In the latest session, Fulcrum Therapeutics Inc (NASDAQ: FULC) closed at $11.36 up 4.12% from its previous closing price of $10.91. In other words, the price has increased by $+0.45 from its previous closing price. On the day, 1183311 shares were traded.
Ratios:
For a deeper understanding of Fulcrum Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 17.71 and its Current Ratio is at 17.71. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.04.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, RBC Capital Mkts on March 13, 2024, initiated with a Outperform rating and assigned the stock a target price of $14.
On September 25, 2023, Goldman started tracking the stock assigning a Neutral rating and target price of $5.
H.C. Wainwright Upgraded its Neutral to Buy on August 23, 2023, whereas the target price for the stock was revised from $5 to $14.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 08 ’24 when Tourangeau Greg sold 4,884 shares for $11.72 per share. The transaction valued at 57,219 led to the insider holds 11,807 shares of the business.
Sapir Alex bought 43,360 shares of FULC for $492,028 on Mar 04 ’24. The insider now owns 43,360 shares after completing the transaction at $11.35 per share. On May 10 ’23, another insider, Tourangeau Greg, who serves as the Principal Accounting Officer of the company, sold 210 shares for $3.31 each. As a result, the insider received 695 and left with 15,992 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, FULC now has a Market Capitalization of 703.58M and an Enterprise Value of 478.18M. For the stock, the TTM Price-to-Sale (P/S) ratio is 250.41 while its Price-to-Book (P/B) ratio in mrq is 2.99. Its current Enterprise Value per Revenue stands at 170.48 whereas that against EBITDA is -4.41.
Stock Price History:
Over the past 52 weeks, FULC has reached a high of $13.70, while it has fallen to a 52-week low of $2.25. The 50-Day Moving Average of the stock is 8.70, while the 200-Day Moving Average is calculated to be 5.32.
Shares Statistics:
For the past three months, FULC has traded an average of 723.71K shares per day and 978.22k over the past ten days. A total of 61.92M shares are outstanding, with a floating share count of 58.69M. Insiders hold about 5.24% of the company’s shares, while institutions hold 94.86% stake in the company. Shares short for FULC as of Feb 29, 2024 were 3.2M with a Short Ratio of 4.42, compared to 3.38M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 5.16% and a Short% of Float of 6.37%.
Earnings Estimates
There are 7 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.44 for the current quarter, with a high estimate of -$0.4 and a low estimate of -$0.46, while EPS last year was -$0.41. The consensus estimate for the next quarter is -$0.45, with high estimates of -$0.4 and low estimates of -$0.48.
Analysts are recommending an EPS of between -$1.59 and -$1.93 for the fiscal current year, implying an average EPS of -$1.78. EPS for the following year is -$1.8, with 7 analysts recommending between -$1.11 and -$2.15.
